Gastric cancer treatment: recent progress and future perspectives

Table 5 Summary of other important investigational targeted therapies for HER2-negative mGC

Target	Approach	Agent	Trial	Phase	Lines	Treatment	Outcomes	References
CLDN18.2	CAR T	CT041	Shen et al	I	2nd line and beyond	CLDN18.2-targeted CAR T cells (CT041)	ORR 57.1%; DCR 75.0%; 6-month OS rate 81.2%; mPFS 4.2 months (GC cohort)	[165]
VEGFR	TKI	Levantinib	EPOC1706	II	1st and 2nd-line	Levantinib + pembrolizumab	ORR 69%; mPFS 7.1 months	[151]
		Levantinib	LEAP-005	II	3rd line and beyond	Levantinib + pembrolizumab	ORR 10%; DCR 48%; mPFS 2.5 months; mOS 5.9 months (GC cohort)	[192]
		Regorafenib	REGONIVO	Ib	3rd line and beyond	Regorafenib + nivolumab	ORR 44%; mPFS 5.6 months	[150]
		Regorafenib	INTEGRATE IIa	III	3rd line and beyond	Regorafenib vs. placebo	mOS 4.5 vs. 4.0 months; mPFS 1.8 vs. 1.6 months	[149]
		Fruquintinib	Zhang, Y., et al	Ib/II	2nd line	Fruquintinib + paclitaxel	mPFS 4 months; mOS 8.5 months; ORR 25.9%; DCR 66.7% (in the 4 mg dose cohort)	[154]
		Fruquintinib	FRUTIGA	III	2nd line	Fruquintinib + paclitaxel vs. placebo + paclitaxel	Ongoing	NCT03223376
FGFR	Monoclonal antibody	Bemarituzumab	FIGHT	II	1st line	Bemarituzumab + mFOLFOX6 vs placebo + mFOLFOX6	ORR 47% vs. 33%; mPFS 9.5 vs. 7.4 months	[172]
FGFR	TKI	Futibatinib	Meric-Bernstam, F., et al	I	3rd line and beyond	Futibatinib	ORR 22.2%; DCR 55.6% (GC cohort)	[169]

ISSN: 1756-8722